Indication intelligence, analysis and sector perception

RegMed’s close: Friday ends the week not as a wall but, more like a door

April 24, 2016 11:53am

Sorry for late review but, sick.

Do you care what happened today, you should … because it has implications to Monday's sector activity?

Subscribe: http://www.regmedinvestors.com/create-account

There is one thing that everyone needs, and that's interpretation and translation of intelligence, not just news or information - we get too much!

To that end, I report a matrix of variables designed for investor’s consideration concerning the stem, cell and gene therapy regenerative medicine portfolio to track and monitor its pricing metric;

The takeaway is that investor need to decide what actions to take, or not take, based on their specific situation.

U.S. stocks closed mixed Friday with tech stocks leading declines after major earnings in the sector disappointed. The Dow and S&P 500 ended little changed on the day and posted their second-straight week of gains amid mixed earnings. The NASDAQ underperformed, closing 0.8% lower after earlier falling 1%. But, the Dow closed higher, above the psychologically key 18,000 level

The NASDAQ closed DOWN -39.66 or -0.80% to 4,906.23 and the DOW closed UP +21.23 or +0.12% to 18,003.75.

A day in the life of the stem, cell and gene therapy RegMed (SCGT & RM) sector – the advance/decline line scenario of our 43 covered companies. Friday, the SCGT&RM sector:

Opened barely positive with an A/DL of 29/10 and 4 flats;

The mid-day stayed positive with an A/DL of 23/18 with 2 flats;

The closing bell rang positive with A/DL of 20/18 with 5 flats

Henry’omics:

The NASDAQ posted two-straight weeks of declines and is 2% lower year-to-date, more than 6% below its 52-week intraday high.

The Dow and S&P are up more than 3% and 2%, respectively, for the year so far, and about 2% or less below their 52-week intraday highs.

The Russell 2000 gained nearly 1% to end in positive territory for the year so far.

The CBOE Volatility Index (VIX), widely considered the best gauge of fear in the market, declined to end slightly above 13.

Investors need to understand that any upside or downside is temporary and that what matters is what and how they respond to the fluctuations.

Remember, everything is a transition; it’s always a fluid market – it is always better to keep one’s eyes on the aftermath of any market and sector move for the next sequence of events!

My pet peeve:

High-frequency trading accounted for 49% of April's daily trading volume of about 6.99 billion shares <according to TABB Group>.

Review my fear gauge or the CBOE Volatility Index (VIX):

Friday traded above 13;
Thursday traded near 13.7;
Wednesday traded near 12.7;
Tuesday traded near 13.4;
Monday traded near 13;
Last, Friday traded below 14;

Who was leading the declines – to of the bottom 5?

Cesca therapeutics (KOOL) closed down -$0.20 to $3.08;
Kite Pharma (KITE) -$0.19 to $50.25;
MiMedx (MDXG) -$0.16 to $8.10;
Fate Therapeutics (FATE) -$0.14 to $$2.06;
Capricor (CAPR) closed down -$0.12 to $4.05

Who was UP – top 5:

bluebird bio (BLUE) closed up +$2.76 to $50.32;
Intrexon (XON) +$1.91 to $29.01;
Applied Genetics Technologies (AGTC) +$1.15 to $18.16;
Spark Therapeutics (ONCE) +$1.11 to $40.77;
Fibrocell (FCSC) closed up +$0.22 to $3.32

Most active sector stocks + and -:

Fate Therapeutics (FATE) -6.36%;
Cesca Therapeutics (KOOL) -5.95%
Caladrius Biosciences (CLBS) -3.67%;

Versus …

Fibrocell (FCSC) +7.10%;
Intrexon (XON) +7.05%;
Applied Genetic Technologies (AGTC) +6.76%

Who was FLAT?

Opexa (OPXA) at $2.40;
uniQure (QURE) at $14.47;
Northwest bio (NWBO) at $1.57;
ReNeuron (RENE.L) at $3.125;

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.